Enoxaparin in ACS

More documents

Recommendations

Info

Is UFH the choice when using SK?o SK + S.C. Heparin didn’t improve outcomecompared with heparinoGISSI- 2oISIS- 3o SK + I.V. Heparin didn’t improve outcomeoGUSTO- 1o SK + I.V. Heparin increase the tendency formajor bleedingAMI-SK Study designSTEMI(n=496)SK1.5 MU i.v.1 h+ aspirin(30 days)(n=491)Enoxaparin30 mgbolus Angiography Follow-upi.v., thenday 8day 301 mg/kg s.c.q 12 h(3–8 days)(n=252)Placebo(3–8 days)(n=239)Angiographyday 8Follow-upday 30SK: StreptokinaseTreatment phaseFollow-up phase
Coronary patency (TIMI flow 2 or 3) at 8 dayssignificantly better with ClexanePa atients (% %)P
Page 1 and 2: Enoxaparin in ACSWhen evidence meet
Page 3 and 4: o DefinitionsAgendao Is UFH w/o dis
Page 5: Superiority ofEnoxaparin over UFHEv
Page 9 and 10: Enoxaparin versus UFH for STEMIOne
Page 11 and 12: No Increase in ICHents% Ev10UFHENOX
Page 13 and 14: New Data from ExTRACT-TIMI 251YEAR
Page 15 and 16: Net Clinical BenefitDeath/MI/Disabl
Page 17 and 18: Summary-23. Net clinical benefit si
Page 19 and 20: Enoxaparin and GP IIb/IIIa inhibito
Page 21 and 22: NICE -3Objectiveso To assess the sa
Page 23 and 24: o DefinitionsAgendao Is UFH w/o dis
Page 25 and 26: Clexane in ACS - My ApproachACSCons
Page 27: Egyptian Guidelines for themanageme

Enoxaparin in ACS

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?